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ABSTRACT  
Objective: Capecitabine (Cape), the first oral prodrug which belongs to the group of fluoro pyrimidines is the most frequently prescribed anticancer 
drug for the treatment of metastatic breast and colorectal cancers. The article describes a selective and robust method for determination of Cape in 
dried blood spots (DBS) by liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
Methods: Cape fortified DBS was punched and extracted with ethyl acetate using capecitabine-d11 as the internal standard (IS). Chromatographic 
separation of Cape and IS from endogenous matrix was performed on Phenomenex Gemini C18 (150 × 4.6 mm, 5µm) column under isocratic 
condition using acetonitrile: 2 mmol ammonium formate (pH 3.0, adjusted with 0.1 % formic acid) (80:20, v/v) as the mobile phase. Detection and 
quantification were carried on a triple quadrupole mass spectrometer, using electro spray ionization technique in the positive ionization mode. 
Results: The method was established over a concentration range of 10-10000 ng/ml. Accuracy, precision, selectivity, recovery, matrix effect and 
stability of the analyte were also estimated and the results were within the acceptance criteria. Further, precise results were obtained using an 
optimum spot volume of 10 µl with good spot homogeneity. Blood samples with hematocrit values varying from 24 % to 45 % gave acceptable 
results with good accuracy and precision. 
Conclusion: The efficiency of dried blood spot sample preparation, short analysis time and high selectivity permits estimation of Cape in a small 
blood volume. The validation results suggest that the method is precise, accurate, and reproducible and can be useful in therapeutic drug 
monitoring of Cape.  




cytidine) is an orally administered fluoropyrimidine carbamate used 
in the treatment of metastatic breast and colorectal cancers [1]. The 
Food and Drug Administration (FDA) had approved Cape (Xeloda®; 
Hoffman-LaRoche, Nutley, NJ) in 2005 as an oral prodrug of 5-
fluorouracil (5-FU) for use as monotherapy in the first line treatment 
of advanced colorectal cancer, adjuvant treatment of patients with 
stage III colon cancer and locally advanced or metastatic breast 
cancer [2]. Moreover, Cape is gradually replacing 5-FU in several 
indications, including gastric cancer. The principle mechanism of 
action of Cape is the inhibition of thymidylate synthase (TS) and 
incorporation into RNA and DNA. After oral administration and 
subsequent absorption across the digestive tract, it is converted to 5-
FU through three sequential enzymatic reactions. It is first 
metabolized to 5-deoxy-5-fluorocytidine (5-DFCR) in the liver by the 
enzyme, carboxylesterase and then to 5-deoxy-5-fluorouridine (5-
DFUR) in the liver and tumor tissue by cytidine deaminase. Finally, it is 
converted intracellularly to 5-FU by thymidine phosphorylase, an 
enzyme that is found in tumor tissue [3-5]. Cape is mainly eliminated 
as metabolites (>95 % of the dose) and the elimination half-life of the 
parent drug and its metabolites is around 1.0 h [5]. The bioavailability 
of Cape is nearly 100 % and its oral pharmacokinetics is linear, 
dependent on dose strength. The plasma protein binding (mainly to 
albumin) is 54% for Cape and about 10 %, 62 %, and 10 % for its 
metabolites 5-DFCR, 5-DFUR and 5-FU respectively [2]. 
In the last decade, dried blood spot (DBS) technique has proved to 
be a superior alternative micro sampling approach for quantitative 
bio analysis of drugs in pharmaceutical research and development. 
Blood micro-collection technique using filter paper has challenged 
the conventional, invasive blood sampling by venepuncture [6, 7]. 
DBS technique offers distinct benefits like reduced sample volume 
collection (usually 10–25 μl), simplified sample collection and 
processing procedures, lack of post-collection processing, lower 
costs of biological sample storage and transport, improved 
(bio)chemical drug stability compared with frozen samples, reduced 
biohazard risk with minimum facility for storage and shipment and 
many more [7-9]. Due to such wide range of advantages it has shown 
considerable promise for toxicokinetics and pharmacokinetic 
analysis and becomes one of the popular micro sampling techniques. 
Several assays have been reported for the determination of Cape 
alone [10, 11], along with its active metabolites in different 
biological matrices such as mouse plasma [12, 13], mouse serum and 
rabbit bile [13] and human plasma [14-23]. In two other reports, 
Cape has been determined together with some multi-cytostatic 
compounds [24, 25]. Mainly, liquid chromatography with UV [10, 11, 
13, 16] and mass spectrometry [12, 14, 15, 17-25] detection has 
been used for the quantification of Cape and/or its active 
metabolites in different matrices.  
In order to derive the benefits of DBS, the analyses must be sensitive 
enough to quantify the target analyte concentration in a few 
microlitres of blood present in a punched DBS disk. Indeed, 
sensitivity may sometimes contribute as one of the major challenges 
for DBS analysis. This issue can be circumvented by using sensitive 
mass spectrometers such as triple quadropole mass spectrometers 
through which sufficient sensitivity and selectivity can be obtained 
with adequate confidence. A review of the literature revealed no DBS 
methods for the quantitation of Cape using LC-MS/MS and as such 
bioanalytical methods, illustrating the quantitative analysis of 
anticancer drugs in DBS are very limited. Thus, the aim of the 
present study was to develop and validate an LC–MS/MS method for 
the quantification of Cape in DBS. The method was fully validated 
based on the current regulatory guidelines [26]. The current method 
provides the simplicity and convenience inherent to the DBS 
technique, faster run time (2.5 min) and specificity through MS/MS 
detection. 
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MATERIALS AND METHODS 
Standards and chemicals 
The reference standard of capecitabine (purity, 99.8%) and 
capecitabine-d11 (IS, purity, 99.0 %) was procured from Toronto 
Research Chemicals Inc. (Ontario, Canada). HPLC grade methanol, 
acetonitrile and ammonium formate were obtained from Merck 
Specialties Pvt. Ltd. (Mumbai, India). Water used in the entire 
analysis was prepared from a Milli-Q water purification system 
procured from Millipore (Bangalore, India). Sample collection cards 
(Whatman® FTA® DMPK-C) were purchased from GE Healthcare 
Europe GmbH (Diegem, Belgium). Harris Micro-Punch® and cutting 
mat were procured from Fisher Scientific. Fresh human blood with 
K3EDTA as the anticoagulant was obtained from Supratech 
Micropath (Ahmedabad, India) and was stored at-20 °C until use.  
Liquid chromatography and mass spectrometry conditions 
A Shimadzu LC-VP HPLC system (Kyoto, Japan) was used for 
chromatographic separation of Cape and IS on Phenomenex Gemini 
C18 (150 mm × 4.6 mm, 5 µm) column, maintained at 40 °C in the 
column oven. The total chromatographic run time was 2.5 min. For 
isocratic elution the mobile phase consisting of acetonitrile and 2 
mmol ammonium formate (pH 3.0, adjusted with 0.1 % formic acid) 
in water (80:20, v/v) and was delivered at a flow-rate of 1.0 mL/min. 
The total eluate from the column was split in 80:20 (v/v) ratio; flow 
directed to the electro spray interface was equivalent to 200 μl/min. 
The auto sampler temperature was maintained at 5 °C and the 
average pressure of the system was 1200 psi.  
A triple quadrupole mass spectrometer, MDS SCIEX API-4000 
(Toronto, Canada), equipped with electro spray ionization and 
operating in positive ionization mode was used for detection of 
analyte and IS. For quantitation, multiple reaction monitoring 
(MRM) was used to monitor precursor → production transitions for 
Cape and IS respectively. Optimized ion source, compound-
dependent parameters and selected MRM transitions for Cape and IS 
are listed in table 1. Analyst classic software version 1.4.2 was used 
to control all parameters of HPLC and MS. 
Standard stock, calibration standards and quality control 
sample preparation 
The standard stock solution of Cape (1000 µg/ml) was prepared 
by dissolving the requisite amount in methanol. Calibration 
standards (CSs) and quality control (QC) samples were prepared 
by spiking blank blood (5 % of total volume of blank blood) with 
standard spiking solutions. A 10 µl fortified blood from each 
sample was spotted on filter paper and used as CS or QC 
samples. CSs were made at 10, 20, 50, 100, 200, 500, 1000, 2000, 
5000 and 10000 ng/ml concentrations while QC samples were 
prepared at five concentration levels, 8000 ng/ml (high quality 
control, HQC), 4000/320 ng/ml (medium quality control, MQC-
1/2), 30 ng/ml (low quality control, LQC) and 10 ng/ml (lower 
limit of quantification quality control, LLOQ QC). Stock solution 
(1000 µg/ml) of the IS was prepared by dissolving 2.0 mg of IS in 
2.0 ml of methanol. An aliquot of 10 µl of this solution was 
further diluted to 20.0 ml in the same diluent to obtain a solution 
of 0.5 µg/ml. 
 
Table 1: Optimized mass parameters for capecitabine and capecitabine-d11 
Parameter Capecitabine  Capecitabine-d11 
Source dependent mass parameters 
Gas 1 (Nebulizer gas)  50 psig 
Ion spray voltage  5800 V 
Heater gas 60 psig 
Turbo heater temperature 300 °C 
Entrance potential  10 V 
Collision activation dissociation 8 psig 
Curtain gas, nitrogen  45 psig 
Quadrupole 1 and 3 Unit mass resolution 
Dwell time 200 ms 
Compound dependent mass parameters 
Declustering potential 50 V 
Cell exit potential 10 V 
Collision energy 30 eV 
MRM transition (m/z) 360.1/244.4 371.3/255.1 
  
 
Fig. 1: Representative snap of dried blood spot sampling 
 
DBS sample preparation  
Sample preparation was performed by spotting 10 µl fortified blood 
sample (CS or QC) onto the center of the printed circle and left to dry 
under ambient room temperature for at least 2 h (fig. 1). A 3-mm 
diameter disc was punched (Harris Micro-Punch®, 3-mm circle) out 
of the sample collection card and taken in eppendorf tubes, followed 
by the addition of 150 µl of 0.1 N HCl. The sample was vortexed and 
sonicated for about 5 min. An aliquot of 50 μl of IS working solution 
was added and vortexed for another 1.0 min. Thereafter the analyte 
and IS were extracted with 2.5 ml of ethyl acetate by vortex mixing 
for 5 min. Samples were centrifuged at 4000 rpm at 10 °C for 10 min. 
The supernatant was transferred into pre-labeled tubes and dried at 
40 °C. The residue was reconstituted with 100 μl of mobile phase, 
briefly vortexed and 10 µl was injected into the LC-MS/MS system 
for analysis. 
Bioanalytical method validation study design 
The method validation of Cape in DBS was done following the US 
FDA guidelines [26] and is similar to our previous work [27, 28].  
A system suitability experiment was performed by injecting six 
consecutive injections using a standard aqueous mixture of Cape 
(4000 ng/ml) and IS (500 ng/ml) at the start of each batch during 
method validation. System performance was studied by injecting one 
extracted LLOQ sample with IS at the beginning of each analytical 
batch and before re-injecting any sample during method validation. 
Carry-over effect of auto sampler was checked to verify any 
carryover of the analyte at the start and at the end of each batch. The 
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design of the experiment comprised of the following sequence of 
injections viz. extracted blank plasma  ULOQ sample  extracted 
blank plasma  LLOQ sample.  
The selectivity of the method towards endogenous plasma matrix 
components was assessed in ten different batches of K3EDTA whole 
blood. The samples were spiked with Cape at the LLOQ level and 
compared with double blank samples (without Cape and IS) for 
selectivity measurements. An aliquot of 10 μl of the samples was 
spotted on the sample collection card and processed. The selectivity 
of the method towards commonly used medications in human 
volunteers was done for acetaminophen, cetirizine, domperidone, 
ranitidine, diclofenac, ibuprofen, nicotine and caffeine in six different 
batches of blood having K3EDTA as an anticoagulant. Their stock 
solutions were prepared by dissolving the requisite amount in 
methanol and water (50:50, v/v). Further, a mixed working solution 
of acetaminophen (1000 µg/ml), cetirizine (20 µg/ml), domperidone 
(1.0 µg/ml), ranitidine (27.5 µg/ml), diclofenac (100 µg/ml), 
ibuprofen (2250 µg/ml), nicotine (5.0 µg/ml) and caffeine (1000 
µg/ml) were prepared in the same diluents, spiked in blood and 
analyzed under the same conditions at LQC and HQC levels in six 
replicates. These sets were processed along with freshly prepared 
CSs and qualifying QC samples in duplicate. As per the acceptance 
criteria, the % accuracy should be within 85 % to 115 %.  
The linearity of the method was determined by analysis of five 
calibration curves containing ten non-zero concentrations. The area 
ratio response for analyte/IS obtained from multiple reaction 
monitoring was used for regression analysis. Each calibration curve 
was analyzed individually by using least square weighted (1/x2) linear 
regression which was finalized during pre-method validation. A 
correlation coefficient (r2) value>0.99 was desirable for all the 
calibration curves. The lowest standard on the calibration curve was 
accepted as the LLOQ, if the analyte response was at least five times 
more than that of drug-free blank blood. In addition, the analyte peak 
of LLOQ sample should be identifiable, discrete and reproducible with 
a precision (% CV) not greater than 20 % and accuracy within 80–120 
%. The deviation of standards other than LLOQ from the nominal 
concentration should not be more than±15 %.  
For determining the intra-batch accuracy and precision, replicate 
analysis of blood samples of Cape was performed on the same day. 
The run consisted of a calibration curve and six replicates of LLOQ 
QC, LQC, MQC-1/2 and HQC samples. Inter-batch accuracy and 
precision were assessed by analyzing five precision and accuracy 
batches on three consecutive validation days. The deviation (% CV) 
at each concentration level from the nominal concentration was 
expected to be within±15 %, except LLOQ, for which it should be 
within±20 %. Similarly, the mean accuracy should not deviate by±15 
%, except for the LLOQ where it can be±20 % of the nominal 
concentration. 
The extraction recovery and matrix effect for the analyte and IS were 
calculated using the following expression as reported previously [29]. 
 
 
Ion suppression/enhancement effects on the MRM LC-MS/MS 
sensitivity were evaluated by the post column analyte infusion 
experiment. A standard solution containing Cape (4000 ng/ml) was 
infused post column via a ‘T’ connector into the mobile phase at 10 
μl/min employing an inbuilt infusion pump. Aliquots of 10 μl of 
extracted control blood were then injected into the column by the 
auto sampler and MRM LC-MS/MS chromatograms were acquired 
for Cape. Any dip in the baseline upon injection of extracted control 
blood (without IS) would indicate ion suppression while a peak at 
the retention time of Cape indicates ion enhancement. 
All stability results were evaluated by measuring the concentration 
of stability samples against nominal concentration at LQC and HQC 
levels. Stock solutions of Cape and IS were checked for short term 
stability at room temperature and long term stability at 5 °C. The 
solutions were considered stable if the deviation from the nominal 
value was within±10.0 %. Bench top (at room temperature) and 
processed sample stability at 2-8 °C were performed at LQC and HQC 
(n = 6 at each level). Long-term stability of dried blood spot samples 
stored at room temperature under ambient conditions was also 
studied at both these levels. The samples were considered stable if 
the deviation of mean calculated concentration of stability QC 
samples was within±15.0 %. Further, the blood stability of Cape on 
the cards incubated at 50 °C was assessed at LQC and HQC level. 
To authenticate the ruggedness of the proposed method, it was 
performed on two precision and accuracy batches. The first batch 
was analyzed by a different analyst while the second batch was 
studied on different equipment of the same make and model. The 
dilution integrity experiment was evaluated by preparing the spiked 
standard at concentration 20000 ng/ml for 1/4th dilution in the 
screened blood. The precision and accuracy for dilution integrity 
standards at 1/4th (5000 ng/ml) dilution was determined by 
analyzing the samples against calibration curve standards. 
In addition to these procedures, other parameters which are DBS-
specific like dried blood spot volume, spot spreadability, and effect 
of hematocrit were also studied in accordance with the EBF 
recommendations for DBS analysis [30]. The acceptance criteria for 
these experiments were same as those for stability assessments. 
RESULTS AND DISCUSSION 
Method development 
In order to check optimum response for Cape and IS, both positive 
and negative ionization modes were tested. The signal intensities 
obtained were much higher in the positive mode than in the negative 
ion mode since Cape and IS have the ability to accept protons. This 
can be attributed to the basic nature of Cape which has a relatively 
high pKa value of 9.5 [23] and, as a result, gets readily protonated 
under the optimized acidic mobile phase conditions. The full scan Q1 
MS spectra obtained by infusing 500 ng/ml solutions of Cape and IS 
contained abundant protonated precursor ions at m/z 360.1 and 
371.3 respectively. The most abundant and characteristic 
productions were found at m/z 244.4 and 255.1 due to the loss of 2-
methyltetrahydrofuran-3,4-diol moiety from the structure of Cape 
and Cape-d11 respectively as shown in fig. 2.  
 
 
Fig. 2: Production mass spectra of (A) capecitabine (m/z 360.1 
→ 244.4, scan range 100-400 amu) and (B) internal standard, 
capecitabine-d11 (m/z 371.3 → 255.1, scan range 100-400 amu) 
in the positive ionization mode 
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During trials, the chromatography was tested on several columns 
like, ACE C18 (150 mm × 4.6 mm, 5.0 µm), Thermo Hypurity C18 
(100 mm × 4.6 mm, 5.0 µm) and Phenomenex Gemini C18 (150 
mm × 4.6 mm, 5.0 µm) to obtain an adequate response, a short 
run time, symmetric peak shapes, minimum matrix interference 
and solvent consumption. This was studied using different mobile 
phase solutions consisting of acidic buffers (acetic acid ammonium 
acetate, formic acid-ammonium format) and organic diluents like 
methanol/acetonitrile. The use of methanol in the mobile phase 
resulted in better selectivity, but the response was not adequate 
for Cape as well as IS, and also the peak shape was poor. Thus, 
acetonitrile was tested in varying proportions with acidic buffers. 
It was observed that the high content of acetonitrile in the mobile 
phase gave a sufficient response with adequate selectivity and 
assisted in eluting the analyte with a retention time of 1.812 min 
within a short run time of 2.5 min. It was found that 2.0 mmol 
ammonium formate (pH 3.0, adjusted with 0.1 % formic acid) in 
water: acetonitrile (20:80, v/v) was most suitable as mobile phase 
for analysis of Cape and IS on Gemini C18 (150 mm × 4.6 mm, 5.0 
µm) column. Low pH buffer enhanced protonation and helped in 
eluting the analyte and IS completely without tailing. Although the 
other two columns afforded adequate retention and response, but the 
peak shape was comparatively poor and hence were not considered for 
further study. The reproducibility of retention time for Cape, expressed 
as % CV was ≤ 1 % for 100 injections on the same column.  
The sensitivity achieved for Cape in the present work was 10.0 ng/ml. 
Representative MRM ion chromatograms in fig. 3 of extracted blank 
human plasma (without IS and analyte), blank plasma fortified with IS 
and Cape at LLOQ and ULOQ with IS demonstrate the selectivity of the 
method. The use of deuterated internal standard helped in the accurate 
quantification of analyte from DBS by maintaining good ionization 
efficiency of the analyte and thereby the accuracy of the data. 
 
 
Fig. 3: MRM ion chromatograms of (A) double blank plasma (without analyte and IS), (B) blank plasma and capecitabine-d11 (IS) (m/z 
371.2 → 255.2), (C) capecitabine (m/z 360.2 → 244.2) at LLOQ and IS, (D) Capecitabine (m/z 360.2 → 244.2) at ULOQ and IS 
 
Cape being an anticancer drug and studied clinically on patients; it is 
crucial to minimize blood loss during subject sample analysis. Hence, 
alternate extraction procedures are necessary, which have a low 
sample requirement for processing without compromising the 
selectivity, sensitivity and efficiency of the developed method. A 
comparative study was done with three conventional extraction 
techniques to validate the potential of the optimized method using 
DBS. The DBS method was tested for % mean recovery and post-
column infusion study for matrix effect with liquid-liquid extraction 
(LLE), solid phase extraction (SPE) and protein precipitation (PP) 
from plasma samples. The mean extraction recoveries obtained 
were 78 %, 85 %, 55 % and 87 % for LLE (with ethyl acetate), SPE 
(on Oasis extraction cartridge), PP (with acetonitrile) and DBS 
method respectively. The recovery obtained by DBS was comparable 
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with the SPE technique. The use of DBS permits a simple and 
straightforward approach for removing the analyte from the 
unwanted matrix components.  
Validation results 
System suitability, system performance and carryover effect 
Precision (%CV) of the system suitability test was observed in the 
range of 0.02 to 0.15 % for the retention time and 0.28 to 1.02 % for 
the area ratio response of Cape/IS. The signal to noise ratio for 
system performance was ≥ 20 for Cape and IS. The carry-over 
evaluation was performed before and after each analytical run to 
ensure that it does not affect the accuracy and the precision of the 
proposed method. There was negligible carryover (≤ 0. 05 %) 
observed during auto sampler carryover experiment in extracted 
blank plasma (without IS and Cape) after subsequent injection of the 
highest CS at the retention time of Cape and IS.  
Linearity, accuracy and precision 
All five calibration curves were linear over the concentration range 
of 10-10000 ng/ml for Cape. A straight-line fit was made through the 
data points by least square regression analysis to give the mean 
linear equation y = (0.0000833±0.0000017) x-(0.00000535 
±0.000018), where y is the peak area ratio of the Cape/ IS and x is 
the concentration of the Cape. The mean correlation coefficient (r2) 
observed, was 0.9995. The accuracy and precision (% CV) for the 
calibration curve standards ranged from 97.3 to 102.4 % and 0.57 to 
2.83 respectively for Cape. The lowest concentration (LLOQ, 10.0 
ng/ml) in the standard curve was measured at a signal-to-noise ratio 
(S/N) ≥ 20. The intra-batch and inter-batch precision and accuracy 
were established from validation runs performed at five QC levels 
(table 2). Precision (% CV) values for the intra-batch ranged from 
1.3-4.6 and the accuracy were within 95.0 to 105.9 % for Cape. 
Similarly, for the inter-batch experiments, precision varied from 2.2–
5.8 % and the accuracy was within 94.6 to 103.3 %.  
Extraction recovery and matrix effect 
The extraction recovery and MFs for the analyte and IS are 
presented in table 3. The extraction recovery for the analyte and IS 
varied from 85.2 to 89.4 % and 83.5 to 89.2 % respectively at all QC 
levels. Quantitative evaluation of matrix effect for the analyte and IS 
was carried out from the peak area response and expressed as MFs. 
The IS-normalized MF for Cape ranged from 1.02 to 1.05 across four 
QC levels. 
 
























HQC (8000) 7689 4.6 96.1 7810 5.8 97.6 
MQC-1 (4000) 4235 2.8 105.9 4124 2.8 103.1 
MQC-2 (320) 316 1.3 98.6 316 2.2 102.8 
LQC (30.0) 28.5 2.1 95.0 28.5 2.5 103.3 
LLOQ QC (10.0) 9.78 3.2 97.8 9.78 3.2 94.6 
CV: Coefficient of variation; n: Number of replicates; LQC: low quality control; MQC: medium quality control; HQC: high quality control; LLOQ QC: 
lower limit of quantitation quality control 
 
Table 3: Extraction recovery and matrix effects for capecitabine and IS (n=6) 
Extraction recovery  
QC  
level 
Capecitabine Capecitabine-d11 (IS) 
Area response Extraction recovery,  
% (A/B) 
Area response Extraction recovery,  
% (A/B)  A B  A B 
LQC 10916 12813 85.2 450241 507600 88.7 
MQC-2 121091 136672 88.6 445086 498976 89.2 
MQC-1 1527309 1708400 89.4 437653 524136 83.5 
HQC 2955532 3416800 86.5 445798 518974 85.9 
Matrix factors  
QC  
level 
Capecitabine Capecitabine-d11 (IS) 
Area response Matrix factor 
(B/C) 
Area response Matrix factor 
(B/C) 
IS-normalized MF 
 C B  C B 
LQC 14095 12813 0.909 580114 507600 0.875 1.04 
MQC-2 146173 136672 0.935 559874 498976 0.891 1.05 
MQC-1  1908826 1708400 0.895 596638 524136 0.878 1.02 
HQC 3746491 3416800 0.912 588405 518974 0.882 1.03 
n: Number of replicates; LQC: Low quality control; MQC: Medium quality control; HQC: High quality control; A: Mean area response of six replicates 
of processed samples (pre-fortified samples); B: Mean area response of six replicate samples prepared by spiking the blank sample with neat 
solution (post-fortified samples); C: Mean area response of six replicate samples prepared in mobile phase (neat samples) 
 
Post-column analyte infusion is a useful tool for visual identification 
of interfering peaks that may cause matrix effects. fig. 4 shows the 
comparison of the profiles obtained by injection of extracted blank 
plasma using SPE, LLE, PP and DBS extraction technique after post-
column infusion of Cape (4000 ng/ml). Any deviation 
(suppression/enhancement) caused by injection of these samples 
from the baseline indicates the existence of matrix effect. As evident 
from the results, except in the case of DBS, some matrix effect or 
signal suppression/enhancement was observed with the other 
extraction techniques between 1.1 and 1.9 min. Nevertheless, no 
such ion suppression or enhancement was found at the retention 
time of Cape with DBS, as evident from the flat baseline.  
Stability, dilution integrity and method ruggedness  
The stability of Cape and IS in DBS and stock solutions was examined 
under different storage conditions. Samples for short-term stability 
remained stable up to 8 h, while the stock solutions, for long term 
stability of Cape and IS were stable for a minimum of 7 d at a 
refrigerated temperature of 2-8 °C. Cape in DBS at room temperature 
was stable for 8 h at 25 °C and under incubation at 50 °C up to 8 d. 
Processed sample stability was evaluated up to 69 h without 
significant loss of the analyte. DBS stored at ambient temperature for 
long term stability experiment was found stable for a minimum period 
of 60 d. The accuracy and precision of different stability experiments 
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in plasma at two QC levels are shown in table 4. The dilution integrity 
experiment was performed with an aim to validate the dilution test to 
be carried out on higher Cape concentration above the upper limit of 
quantification (ULOQ). The precision and accuracy for dilution 
integrity of 1/4th dilution were 0.8-1.2 % and 101.2-106.0 % 
respectively. The precision and accuracy results for method 
ruggedness with different columns and analysts were within 0.8-4.0 % 
and 95.6-106.6 % for Cape respectively. 
Effect of spot volume, sample spread ability and impact of 
hematocrit 
To test the effect of DBS volume on the accuracy and precision of the 
method, different spot volumes (10, 15, 20, 25 and 30 μl) at LQC and 
HQC levels were analyzed in triplicate. It was found that at volumes ≥ 
20 μl the results were less accurate compared to lower volumes (10 
and 15 μl) as shown in table 5. In the present work 10 μl spot volume 
was selected based on better accuracy and precision data obtained. 
 
Fig. 4: Comparison of extraction techniques (LLE, PP, SPE and 
DBS) for matrix effect by post-column infusion technique
 
Table 4: Stability of capecitabine in DBS under different conditions (n = 6) 






Precision (% CV) 
Bench top stability, 8 h 8000 7810±69.6 97.6 0.89 
30.0 28.1±0.63 93.3 2.24 
Processed sample stability, at 2-8 °C, 69 h  8000 8150±83.4 94.5 1.02 
30.0 31.9±0.81 99.1 2.54 
Stability under incubation at 50 °C up to 8 d  8000 7900±44.6 98.7 0.56 
30.0 29.3±0.40 96.7 1.36 
Long-term stability at ambient temperature, 60 d 8000 8100±122.7 101.2 1.51 
30.0 31.0±0.94 103.3 3.03 
 n: Number of replicates; SD: Standard deviation; CV: coefficient of variation 
 
Table 5: Effect of DBS volumes on the quality control sample concentration (n = 3) 
QC level Spot volume (µl) Concentration found (ng/ml) Accuracy (%) Precision (% CV) 
Low quality control (30.0 ng/ml) 10 30.4 101.3 3.2 
15 29.1 97.0 3.7 
20 28.5 95.1 2.7 
25 27.9 93.0 5.3 
30 26.7 89.1 4.2 
High quality control (8000 ng/ml) 10 7946 99.3 2.1 
15 8262 103.3 1.7 
20 7643 95.5 3.4 
25 7427 92.8 2.4 
30 7144 89.3 2.8 
 n: Number of replicates; CV: coefficient of variation 
 
Table 6: Impact of hematocrit value on the quality control sample concentration (n = 3) 




Low quality control (30.0 ng/ml) 24.5 30.7 102.3 4.5 
33.6 28.1 93.6 2.5 
44.2 27.8 92.7 3.6 
High quality control (8000 ng/ml) 24.5 7856 98.2 1.2 
33.6 7806 97.6 1.9 
44.2 7764 97.1 3.8 
 
The impact of sample spreadability was investigated by spotting 10 
μl of spiked K3EDTA whole blood at LQC and HQC levels in triplicate. 
A 3 mm disc punched and analyzed showed acceptable accuracy and 
precision results. The accuracy varied from 94.7 % to 102.3 % and 
the precision (% CV) was in the range of 1.5-5.2 % at the studied QC 
levels.  
The effect of hematocrit, which defines the relative volume of red 
blood cells in whole blood greatly, influences the spot 
homogeneity. QC samples were prepared from whole blood having 
different hematocrit levels (24.5 %, 33.6 % and 44.2 %). The 
spiked samples at LQC and HQC levels (three replicates) were 
prepared using these whole blood samples with different 
hematocrit levels. The accuracy and precision of DBS samples 
ranged from 92.7-102.3 % and ≤ 4.5 % respectively (table 6). 
These results indicate no impact of hematocrit on the accuracy and 
precision of the developed method. 
Comparison of the DBS method with reported methods for 
capecitabine 
The developed method is the first attempt to determine Cape in 
DBS using any known analytical technique. Moreover, it employs 
the lowest sample volume for processing as compared to all 
previous methods [10, 11, 14-23]. Though the sensitivity is less 
compared to some of these methodologies [15, 17, 18] but the 
Shrivastav et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 12, 238-245 
244 
present method requires only 2.5 min for chromatographic 
analysis, which is less than these methods. A comparative 
summary of existing methods and the salient features of the 
developed DBS method are shown in table 7. 
 
Table 7: Comparison of salient features of chromatographic methods developed for capecitabine in human plasma 




Retention time (min); Run time (min)  Ref. 
1 HPLC-UV 1000  156–20000 6.223; 10.0  [10] 
2 HPLC-UV 1000  50-10000 4.9; 8.0  [11] 
3a HPLC-MS 500  50-10000  18.19; 24.0 [14] 
4a LC-MS/MS 250  5.00-1000 1.43; 3.0  [15] 
5a HPLC-UV 500  25-10000 20.4; 30  [16] 
6a LC-MS/MS 500  1-5000 12.14; 14.0 [17] 
7a LC-MS/MS 50  1-1000 2.47; 4.0  [18] 
8a LC-MS/MS 500  150-3000 7.83; 15.0 [19] 
9a LC-MS/MS 200  10-1000 11.5; 15.0  [20] 
10a LC-MS 500  25-10000 9.0; 15.0 [21] 
11a LC-MS/MS 100  50-6000 5.01; 9.0  [22] 
12a LC-MS/MS 100  10-5000 8.2; 10.5  [23] 
13b LC-MS/MS 10 (DBS)  10-10000 1.81; 2.5  PM 
 n: Number of replicates; CV: coefficient of variation, aAlong with metabolites; bIn dried blood spots (DBS); PM: present method.  
CONCLUSION 
A rugged and robust dried blood spots assay coupled with a LC–
MS/MS was developed and validated for the extraction and analysis 
of Cape in human whole blood. The method offers significant 
advantages over those previously reported, in terms of lower sample 
requirements, the simplicity of extraction procedure and overall 
analysis time. The assay is able to quantify Cape over a dynamic 
concentration range of 10-10000 ng/ml in DBS and the results 
acquired were highly reproducible for 10 µl of spotting volume. The 
recovery obtained was quantitative and consistent across QC levels 
with no interference from endogenous or exogenous matrix 
components. The assay demonstrated the satisfactory long-term 
stability of Cape in DBS under ambient conditions. Further, blood 
samples having hematocrit values between 24 and 45 % 
demonstrated acceptable accuracy and precision in the quantitative 
measurements. This LC-MS/MS assay can be readily applied to the 
analysis of Cape in clinical laboratories for pharmacokinetics/ 
bioequivalence studies. 
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